PARTNER 3 has been one of the most closely watched clinical trials in cardiology for many years now. Michael J. Mack, MD, presented a seven-year update during a packed session at TCT 2025. 

The Cardiovascular Research Foundation and Fogarty Innovation are joining forces to help innovative researchers and technologies flourish in today's competitive medtech industry. The two organizations made the partnership official at TCT 2025 in San Francisco. 

The SELUTION SLR Drug-Eluting Balloon was the topic of two different late-breaking clinical trials at TCT 2025. Both studies found that the device was noninferior to traditional treatments after one year. Long-term data are still needed. 

The guidewire was built specifically with Medtronic's own Evolut platform in mind. However, it is also compatible with all other commercially available TAVR systems.

PCI Navigator from Heartflow was designed to help cardiologists plan ahead for percutaneous coronary interventions before they even step foot into the cath lab. It assesses a patient’s CCTA results and creates a state-of-the-art 3D model.

Kimberly Campbell, RN, nurse practitioner, Saint Luke's Cardiovascular Consultants, explains how her health system took a heart team approach toward peripheral artery disease. 

This year marks the 37th annual gathering of the popular Transcatheter Cardiovascular Therapeutics conference. What started as a small gathering in 1988 has grown into one of interventional cardiology’s biggest events.

"We're constantly trying to keep our fingers on the pulse of what's happening in the real world," explained Joan Michaels, RN, director of the STS/ACC TVT Registry.  "This is not a trial; this is real-world experience."